Skip to content
AnalystLens

Exelixis Annual Report, Year Ended Dec 29, 2017

Filing Date
Filed February 26, 2018
Period End
December 29, 2017
Security
EXEL
One revenue dollarkept$0.34
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’17May ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · May ’22May ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-K filed February 26, 2018. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. reported a return to profitability in 2017, with net income of $154.2 milliona compared with a net loss of $70.2 million in 2016.

Total revenues rose to $452.5 millionb from $191.5 million, driven by net product revenues of $349.0 million (up from $135.4 million), led by CABOMETYX at $324.0 million, and collaboration revenues of $103.5 million. The company retired all of its outstanding debt during 2017, including the $80.0 million Silicon Valley Bank term loan and the Deerfield Notes for a payment of $123.8 million, leaving no debt on the balance sheet at December 31, 2017. Cash and investments were $457.2 million at year-end, of which $452.0 million was available for operations.

The filing states that the company's near-term prospects depend heavily on the commercial success of CABOMETYX in advanced renal cell carcinoma. On December 19, 2017, the FDA approved CABOMETYX for previously untreated advanced RCC, and the company plans to submit a supplemental New Drug Application for previously treated advanced hepatocellular carcinoma in the first quarter of 2018 following positive CELESTIAL trial results. Cobimetinib (COTELLIC) is marketed with Genentech, and the company resolved its arbitration with Genentech in July 2017 through an amended, more favorable revenue and cost-sharing arrangement.

Management expects research and development and selling, general and administrative expenses to increase in 2018, and notes that adoption of ASU 2014-09 will reduce accumulated deficit by approximately $260 millionc for collaboration agreements with Ipsen and Takeda. The filing also flags material risks, including competition from immunotherapies such as nivolumab, pricing and reimbursement pressure, possible generic competition for cabozantinib (the FDA published draft bioequivalence guidance in February 2018), dependence on collaboration partners, and a planned relocation of corporate headquarters to Alameda, California in 2018. The company reported 372 full-time equivalent employees as of December 31, 2017.

Key Highlights

  1. Net income of $154.2 million for 2017 versus a net loss of $70.2 million in 2016; diluted EPS of $0.49.
  2. Total revenues of $452.5 million, up from $191.5 million in 2016; net product revenues of $349.0 million, of which CABOMETYX contributed $324.0 million.
  3. Retired all outstanding debt in 2017, including the $80.0 million term loan with Silicon Valley Bank and the Deerfield Notes for $123.8 million; debt was zero at December 31, 2017.
  4. Cash and investments of $457.2 million at December 31, 2017, of which $452.0 million was available for operations.
  5. FDA approved CABOMETYX for previously untreated advanced RCC on December 19, 2017, about two months ahead of the PDUFA action date; an sNDA for previously treated advanced HCC is planned for Q1 2018 following CELESTIAL.
  6. Resolved the Genentech arbitration in July 2017 with an amended, more favorable revenue and cost-sharing arrangement for COTELLIC, effective July 1, 2017.
  7. Income tax provision was $4.4 million, and net operating loss carry-forwards were approximately $1,529 million across federal and state jurisdictions, with a full valuation allowance on remaining NOLs.

Follow one dollar

Of each $1.00 of revenue in FY2017, Exelixis kept $0.34.

  1. Revenue$452.5M100.0%
  2. Cost of revenue−$15.1M3.3%
  3. Gross profit$437.4M96.7%
  4. Operating costs−$271.5M60.0%
  5. Operating income$165.9M36.7%
  6. Interest, other & tax−$11.7M2.6%
  7. Net income$154.2M34.1%
Computed from 10-KFY2017filed February 26, 2018Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2017 revenue went

$452.5M
  • SG&A: $159.3M, 35% of revenue
  • Net income: $154.2M, 34% of revenue
  • R&D: $112.2M, 25% of revenue
  • Cost of revenue: $15.1M, 3.3% of revenue
  • Interest, other & tax: $11.7M, 2.6% of revenue

Kept 34% as net income

Full revenue history →

Financial Statements

FY2017 against FY2016

Line itemFY2017FY2016Change
Revenue$452.48M$37.17M+1117.3%
Cost of Revenue$15.07M$3.90M+286.8%
Gross Profit$437.41M$33.28M+1214.5%
R&D Expenses$112.17M$95.97M+16.9%
SG&A Expenses$159.33M$116.14M+37.2%
Operating Expenses$286.57M$219.58M+30.5%
Operating Income$165.91M-$28.12M+689.9%
Interest Expense$8.68M$33.06M−73.7%
Net Income$154.23M-$70.22M+319.6%
EPS (Basic)$0.52$-0.28+285.7%
EPS (Diluted)$0.49$-0.28+275.0%
Shares Outstanding (Basic)293.59M250.53M+17.2%
Shares Outstanding (Diluted)312.00M250.53M+24.5%

Frequently Asked Questions

  1. What drove the swing from a net loss in 2016 to net income in 2017?

    Total revenues increased by $261.0 million to $452.5 million, primarily from net product revenues of $349.0 million, up $213.6 million, mainly due to CABOMETYX sales growth. Operating income was $165.9 million in 2017 compared with an operating loss of $28.1 million in 2016. Other expenses, net, declined to $7.3 million from $42.1 million, largely because interest expense fell to $8.7 million from $33.1 million after debt repayment.

  2. How much debt does Exelixis have after the 2017 repayments?

    None. The filing states that as of December 31, 2017, total debt was zero, compared with $189.1 million at December 31, 2016. The company paid $185.8 million in principal repayments during 2017 for the Deerfield Notes and the Silicon Valley Bank term loan.

  3. What are the key near-term regulatory catalysts for CABOMETYX?

    The company plans to submit a supplemental New Drug Application to the FDA in the first quarter of 2018 for CABOMETYX in previously treated advanced HCC, based on the CELESTIAL trial, which showed median overall survival of 10.2 months versus 8.0 months with placebo. Partner Ipsen intends to submit a regulatory dossier to the EMA in the first half of 2018.

  4. What are the main risks highlighted for investors?

    The filing emphasizes dependence on CABOMETYX's commercial success in advanced RCC, competition from immunotherapies such as BMS's nivolumab and the nivolumab-ipilimumab combination, pricing and reimbursement pressure, potential generic competition after the February 2018 FDA draft bioequivalence guidance for cabozantinib, reliance on collaboration partners Ipsen, Takeda and Genentech, and the planned headquarters relocation to Alameda in 2018.